Viking Therapeutics Inc (NASDAQ:VKTX) fell 5.5% on Tuesday . The company traded as low as $6.19 and last traded at $6.34. 1,801,473 shares traded hands during mid-day trading, an increase of 8% from the average session volume of 1,667,448 shares. The stock had previously closed at $6.71.
A number of research firms have recently weighed in on VKTX. BidaskClub raised Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 7th. Maxim Group set a $8.00 target price on Viking Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 12th. ValuEngine lowered Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Roth Capital set a $6.00 target price on Viking Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Viking Therapeutics in a research note on Friday, November 10th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $7.00.
The company has a market capitalization of $325.58, a P/E ratio of -7.55 and a beta of 2.26.
COPYRIGHT VIOLATION NOTICE: “Viking Therapeutics (VKTX) Shares Down 5.5%” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3226544/viking-therapeutics-vktx-shares-down-5-5.html.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.